CardioExchange Archive

August 5th, 2013

Faint PRAISE: 13-Year Delay in Publication of a Major Clinical Trial Sparks Criticism

Larry Husten, PHD

Thirteen years after first being presented, the results of the PRAISE-2 trial finally have been published in JACC: Heart Failure. The trial itself is now largely irrelevant to current clinical practice, as the hypothesis it tested has long been abandoned, but the long delay in publication may serve to bring even more awareness to the issue […]

---

December 7th, 2012

Should Body Weight Influence Choice of Antihypertensive Therapy?

Larry Husten, PHD

The hypertension field has been troubled by repeated observations that normal weight patients have more cardiovascular (CV) events than obese patients. Now a new analysis of a large hypertension trial confirms this finding but also suggests that it may be explained by either an adverse effect of diuretics or a protective effect of calcium-channel blockers in non-obese hypertensives. […]

---

January 14th, 2011

Combination Therapy Beats Single Therapy As Initial Antihypertensive Therapy

Larry Husten, PHD

In the ACCELERATE (Aliskiren and the calcium channel blocker amlopdipine combination as an initial treatment strategy for hypertension control) trial, more than 1200 patients with early essential hypertension were randomized to either aliskiren, amlodipine, or the combination of the two drugs for 4 months. The results, which have been published online in the Lancet, showed […]

---